Short answer
REGENXBIO Inc. (RGNX) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $9M (down 69.2% year over year) with net income of −$41M.
Q3 2026 key financials · XBRL
- Revenue
- $9M
- −69.2% YoY · −91.5% QoQ
- Net income
- −$41M
- +34.2% YoY · −279.4% QoQ
- Operating margin
- -387.8%
- EPS (diluted)
- −$0.62
- +48.3% YoY · −240.9% QoQ
Source: XBRL data from the REGENXBIO Inc. (RGNX) Q3 2026 10-Q on SEC EDGAR. USD.
REGENXBIO Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $9.2M, down $20.6M YoY from $29.7M, driven by lower Zolgensma royalties
- Operating loss $35.5M, versus $52.4M YoY; operating margin -387.8% vs -176.3%
- Best performer: Itvisma royalties $2.8M; worst: Zolgensma royalties $2.4M, down $21.2M YoY
- Cash, equivalents and marketable securities $251.0M; operating cash outflow $99.8M versus $71.7M YoY
- $107.8M equity offering and $18.9M ATM proceeds; liquidity expected into late fourth quarter 2027, with substantial going-concern doubt
Risk Factors
- No material changes from 2025 Form 10-K risk factors
- Carried-forward risks remain the company’s material disclosed risks
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other REGENXBIO Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.